Orgenesis (NASDAQ:ORGS) and Oragenics (NYSEAMERICAN:OGEN) Head to Head Comparison

Earnings & Valuation

This table compares Orgenesis and Oragenics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orgenesis	$662,000.00	0.72	-$55.36 million	N/A	N/A
Oragenics	$40,000.00	134.23	-$10.57 million	($21.42)	-0.06

Oragenics has lower revenue, but higher earnings than Orgenesis.

Volatility & Risk

Orgenesis has a beta of 2.63, meaning that its stock price is 163% more volatile than the S&P 500. Comparatively, Oragenics has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500.

Institutional and Insider Ownership

22.6% of Orgenesis shares are held by institutional investors. Comparatively, 18.7% of Oragenics shares are held by institutional investors. 5.7% of Orgenesis shares are held by company insiders. Comparatively, 10.1% of Oragenics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Orgenesis and Oragenics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Orgenesis	-3,827.81%	N/A	-130.18%
Oragenics	N/A	-3,614.27%	-324.80%

Summary

Orgenesis beats Oragenics on 5 of the 9 factors compared between the two stocks.

About Orgenesis

Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.

About Oragenics

Oragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.